Last reviewed · How we verify
NCT03449706: ACS
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
trial testing Early combination anti-retroviral treatment in HIV in 70 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 1 September 2017 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 January 2028 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Early combination anti-retroviral treatment — full drug profile →
Conditions studied
- HIV — all drugs for HIV →
- Seroconversion, HIV — all drugs for Seroconversion, HIV →
Sponsor
University Hospital, Ghent
Who can join
Adults 18 to 65, any sex, with HIV or Seroconversion, HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (HIV) viral reservoir, established during early HIV infection and responsible for viral rebound at treatment interruption, evolve in individuals who start combination anti-retroviral therapy (cART) during acute seroconversion. Recently infected patients will be selected based on Fiebig staging for an in depth sampling protocol at different timepoints during a 2 year follow up period. Colonbiopsies, lymphnode resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be performed. Immunological, virological and genome expression analysis will be performed on the gathered samples.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.
Jensen BO, Knops E, Cords L, Lübke N, et al · · 2023 · cited 126× · PMID 36807684 · DOI 10.1038/s41591-023-02213-x -
Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir.
De Clercq J, De Scheerder MA, Mortier V, Verhofstede C, et al · · 2023 · cited 17× · PMID 38250083 · DOI 10.3389/fimmu.2023.1337316 -
Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment.
Dijkstra M, Prins H, Prins JM, Reiss P, et al · · 2021 · cited 9× · PMID 34845066 · DOI 10.1136/bmjopen-2020-048582 -
Evolution of the HIV-1 integration site landscape and inducible reservoir in early-treated people.
Struyve T, Pardons M, De Clercq J, Termote L, et al · · 2025 · cited 1× · PMID 41289275 · DOI 10.1371/journal.ppat.1013702 -
Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study.
De Clercq J, De Scheerder MA, Vanherrewege S, Caluwé E, et al · · 2024 · cited 1× · PMID 39403428 · DOI 10.1016/j.jve.2024.100392
Verify or expand the search:
- PubMed search for NCT03449706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03449706 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 14 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03449706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing